Before You Buy Gilead Sciences Stock, Read This
At the beginning of this month, the U.S. Food and Drug Administration (FDA) authorized Gilead Sciences's (NASDAQ: GILD) remdesivir for the treatment of severely ill COVID-19 patients. Currently, remdesivir is the first drug authorized for the disease that has demonstrated efficacy in placebo-controlled, phase 3 clinical trials.
While most are excited about the potential relief Gilead could bring to COVID-19 patients, a group of smart investors has argued that the company itself is a poor investment opportunity due to an overlooked detail in remdesivir's data. Believe it or not, these individuals actually present a very good case. Let's see why.
The gist of skepticism surrounding remdesivir's success seems to stem from a question asked by a Bank of America analyst during Gilead's recent earnings call:
Source Fool.com
